HEALTH-RELATED QUALITY OF LIFE AND HEALTH UTILITY AMONG BRAZILIAN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM BRAZIL
- 1Novartis Biociências S.A., São Paulo, SP, Brazil
- 2Associação Brasileira de Câncer do Sangue (Abrale), São Paulo, SP, Brazil
Abstract
Background: Advances in tyrosine kinase inhibitor (TKI) therapy have substantially improved survival outcomes for patients with chronic myeloid leukemia (CML). As patients increasingly achieve long-term disease control, health-related quality of life (HRQoL) has become an important treatment outcome. Aim: To characterize HRQoL and health utility scores among Brazilian patients with chronic-phase CML receiving TKI and to explore associations between treatment line and comorbidity burden on patient-reported outcomes. Materials and methods: This prospective, cross-sectional, non-interventional study enrolled Brazilian adults (≥ 18 years) with confirmed chronic-phase CML receiving an approved TKI for at least 1 month. Participants were recruited through the Brazilian Blood Cancer Association (ABRALE). Following ethics committee approval, eligible participants provided electronic informed consent and completed structured self-administered digital questionnaires through an electronic platform. HRQoL was assessed using the EuroQol 5-Dimension 3-Level questionnaire (EQ-5D-3L) and the EQ Visual Analogue Scale (EQ-VAS). EQ-5D-3L utility scores were derived using the Brazilian time trade-off (TTO) value set developed by Santos et al. Patients unwilling or unable to provide informed consent or currently participating in an interventional clinical trial were excluded. Results: Of 216 respondents, 137 were eligible for inclusion after excluding patients with non–chronic-phase CML (n = 4), participation in or uncertainty regarding participation in an interventional clinical trial (n = 22), no current TKI treatment (n = 46), or age < 18 lt; 18 years (n = 7). Of these, 99 completed the EQ-5D-3L and were included in the HRQoL analysis. Participants were predominantly female (61.6%), aged 40–59 years (46.5%), White (65.7%), residing in Southeastern Brazil (52.5%), and had a university degree (41.4%); 52.5% received care through private health insurance. Regarding treatment history, 40 (40.4%) patients were receiving first-line (1L) TKI therapy, 35 (35.4%) second-line (2L) therapy, and 24 (24.2%) third-line or later (≥ 3L) therapy. Overall, 45.5% of patients reported no comorbidities, 32.3% reported one comorbidity, and 22.2% reported two or more comorbidities. The mean EQ-5D-3L utility score was 0.748 (95% CI, 0.716–0.780), and the mean EQ-VAS score was 73.5 (95% CI, 69.9–77.0). Mean EQ-5D-3L utility scores were 0.766 (95% CI: 0.720–0.812), 0.762 (95% CI: 0.715–0.810), and 0.696 (95% CI: 0.615–0.777) among patients receiving 1L, 2L, and ≥ 3L therapy, respectively. HRQoL decreased progressively with increasing comorbidity burden, with mean EQ-5D-3L utility scores of 0.826 (95% CI, 0.784–0.869) among patients without comorbidities, 0.706 (95% CI, 0.659–0.753) among those with one comorbidity, and 0.648 (95% CI, 0.582–0.714) among those with ≥ 2 comorbidities (Kruskal–Wallis p < 0.001). Conclusion: This study provides one of the first real-world assessments of HRQoL and health utility among Brazilian patients with chronic-phase CML receiving TKI therapy. Overall, HRQoL was favorable; however, lower utility scores were observed among patients receiving third-line or later treatment and among those with a higher comorbidity burden. The progressive decline in HRQoL with increasing comorbidity burden highlights the impact of comorbid conditions on patient well-being beyond leukemia control alone.
Related
- Association of Non‐Cytochrome P450 3A4‐Metabolized Statins Versus Atorvastatin With Major Adverse Cardiovascular Events in Patients With Cancer Receiving Tyrosine Kinase Inhibitors: A Propensity Score–Matched Target Trial Emulation
- Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors (BTKi): A Retrospective Study From a Tertiary Healthcare Center in North India.
- Bone Marrow Aplasia Under Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Rare and Unpredictable Complication.
- Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL‐2 Inhibitors
- Early on-treatment alpha-fetoprotein and des-gamma-carboxy prothrombin responses are associated with outcomes in unresectable hepatocellular carcinoma receiving transarterial chemoembolization, tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors.
BibTeX
@article{kashiura2026healthrelated,
title = {{HEALTH-RELATED QUALITY OF LIFE AND HEALTH UTILITY AMONG BRAZILIAN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM BRAZIL}},
author = {Diego KASHIURA and Diogo NOIN DE OLIVEIRA and Ana Beatriz MACHADO DE ALMEIDA and Alessandro BIGONI and Priscila RAUPP DA ROSA and Leonardo Hiago GATTAS and Michelly Yumi TUBONE DONI and Jamile COUTRIM DALRI and Nina MELO and Janaina ROSENBURG GIOSEFF and Catherine MOURA DA FONSECA PINTO and Lucas Kaoru KOBO FERREIRA},
journal = {Hematology, Transfusion and Cell Therapy},
year = {2026},
month = oct,
doi = {10.1016/j.htct.2026.107507},
url = {https://doi.org/10.1016/j.htct.2026.107507},
note = {CC BY},
}
RIS
TY - JOUR
TI - HEALTH-RELATED QUALITY OF LIFE AND HEALTH UTILITY AMONG BRAZILIAN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITORS: REAL-WORLD EVIDENCE FROM BRAZIL
AU - Diego KASHIURA
AU - Diogo NOIN DE OLIVEIRA
AU - Ana Beatriz MACHADO DE ALMEIDA
AU - Alessandro BIGONI
AU - Priscila RAUPP DA ROSA
AU - Leonardo Hiago GATTAS
AU - Michelly Yumi TUBONE DONI
AU - Jamile COUTRIM DALRI
AU - Nina MELO
AU - Janaina ROSENBURG GIOSEFF
AU - Catherine MOURA DA FONSECA PINTO
AU - Lucas Kaoru KOBO FERREIRA
PY - 2026
DA - 2026/10/23
JO - Hematology, Transfusion and Cell Therapy
DO - 10.1016/j.htct.2026.107507
UR - https://doi.org/10.1016/j.htct.2026.107507
AB - Background: Advances in tyrosine kinase inhibitor (TKI) therapy have substantially improved survival outcomes for patients with chronic myeloid leukemia (CML). As patients increasingly achieve long-term disease control, health-related quality of life (HRQoL) has become an important treatment outcome. Aim: To characterize HRQoL and health utility scores among Brazilian patients with chronic-phase CML receiving TKI and to explore associations between treatment line and comorbidity burden on patient-reported outcomes. Materials and methods: This prospective, cross-sectional, non-interventional study enrolled Brazilian adults (≥ 18 years) with confirmed chronic-phase CML receiving an approved TKI for at least 1 month. Participants were recruited through the Brazilian Blood Cancer Association (ABRALE). Following ethics committee approval, eligible participants provided electronic informed consent and completed structured self-administered digital questionnaires through an electronic platform. HRQoL was assessed using the EuroQol 5-Dimension 3-Level questionnaire (EQ-5D-3L) and the EQ Visual Analogue Scale (EQ-VAS). EQ-5D-3L utility scores were derived using the Brazilian time trade-off (TTO) value set developed by Santos et al. Patients unwilling or unable to provide informed consent or currently participating in an interventional clinical trial were excluded. Results: Of 216 respondents, 137 were eligible for inclusion after excluding patients with non–chronic-phase CML (n = 4), participation in or uncertainty regarding participation in an interventional clinical trial (n = 22), no current TKI treatment (n = 46), or age < 18 lt; 18 years (n = 7). Of these, 99 completed the EQ-5D-3L and were included in the HRQoL analysis. Participants were predominantly female (61.6%), aged 40–59 years (46.5%), White (65.7%), residing in Southeastern Brazil (52.5%), and had a university degree (41.4%); 52.5% received care through private health insurance. Regarding treatment history, 40 (40.4%) patients were receiving first-line (1L) TKI therapy, 35 (35.4%) second-line (2L) therapy, and 24 (24.2%) third-line or later (≥ 3L) therapy. Overall, 45.5% of patients reported no comorbidities, 32.3% reported one comorbidity, and 22.2% reported two or more comorbidities. The mean EQ-5D-3L utility score was 0.748 (95% CI, 0.716–0.780), and the mean EQ-VAS score was 73.5 (95% CI, 69.9–77.0). Mean EQ-5D-3L utility scores were 0.766 (95% CI: 0.720–0.812), 0.762 (95% CI: 0.715–0.810), and 0.696 (95% CI: 0.615–0.777) among patients receiving 1L, 2L, and ≥ 3L therapy, respectively. HRQoL decreased progressively with increasing comorbidity burden, with mean EQ-5D-3L utility scores of 0.826 (95% CI, 0.784–0.869) among patients without comorbidities, 0.706 (95% CI, 0.659–0.753) among those with one comorbidity, and 0.648 (95% CI, 0.582–0.714) among those with ≥ 2 comorbidities (Kruskal–Wallis p < 0.001). Conclusion: This study provides one of the first real-world assessments of HRQoL and health utility among Brazilian patients with chronic-phase CML receiving TKI therapy. Overall, HRQoL was favorable; however, lower utility scores were observed among patients receiving third-line or later treatment and among those with a higher comorbidity burden. The progressive decline in HRQoL with increasing comorbidity burden highlights the impact of comorbid conditions on patient well-being beyond leukemia control alone.
SN - 2531-1379
SN - 2531-1387
ER -